A new study, done in part at the UK Markey Cancer Center, shed light on why lung cancer cells can resist therapeutic cancer treatment.

Markey’s Dr. Timothy Mullet appointed to Commission on Cancer

Dr. Timothy Mullet

UK Markey Cancer Center’s Dr. Timothy Mullett has been appointed to the Commission on Cancer (CoC), a consortium of professional organizations dedicated to improving survival and quality of life for cancer patients across the country. Mullett is one of eight surgeons from across the country elected to represent the fellowship for a three-year term.

Established by the American College of Surgeons (ACoS) in 1922, the multidisciplinary CoC establishes standards to ensure high-quality, multidisciplinary and comprehensive cancer care delivery in healthcare settings; conducts surveys in healthcare settings to assess compliance with those standards; collects standardized data from CoC-accredited healthcare settings to measure cancer care quality; uses data to monitor treatment patterns and outcomes and enhance cancer control and clinical surveillance activities; and develops effective educational interventions to improve cancer prevention, early detection, cancer care delivery and outcomes in healthcare settings.

Mullett began his career at UK in 1996 as a thoracic surgeon treating heart issues, but quickly changed his focus to one of Kentucky’s biggest problems: lung cancer. In addition to co-leading one of the major components of the Kentucky LEADS Collaborative to improve lung cancer survival, he also serves as medical director for both the UK Markey Cancer Center Affiliate and Research Networks.


Next steps: